Corsair Pharma logo

Corsair Pharma

Recent Finacing

Series B

Recent Raise

$23M


Corsair Pharma is a biopharmaceutical company that is developing a transdermal treprostinil prodrug patch to improve medication therapeutic profiles and provide treatment options for patients with PAH.

Total Funding

$23M

Headquarters

Sunnyvale, USA

Founded

N/A

Focus Areas

Biopharmaceutical
Transdermal Drug Delivery
Pulmonary Arterial Hypertension Treatment

Investors

Primavera Capital logo
New Rhein Healthcare Investors logo
Plaisance Capital logo
Junson Capital logo
Midas Capital logo